Galectin Therapeutics has reported new preclinical data that show its galectin inhibitors, GR-MD-02 and GM-CT-01, have significant therapeutic effects on fibrosis regression and cirrhosis reversal. Results were published in an article titled, Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease, in PLOS ONE, an international, open-access journal with rigorous peer review. In the preclinical study, fibrosis was induced in rats by ...